Orano Med
Roberto Rivera serves as a Senior Operator at Orano Med since April 2023, overseeing commercial cell culture contract manufacturing and managing project documentation. Previously, Roberto worked as a Viral Vector Production Associate at Genezen and as a Senior Associate at Abzena, demonstrating extensive experience in aseptic processing and production operations. Notable roles include Aseptic Production Operator at Gilead Sciences, where responsibilities included managing sterile tank operations and optimizing processes through Lean principles. Early career experience includes positions at B. Braun Medical, Pacira Pharmaceuticals, Par Pharmaceutical, and Teva Pharmaceuticals, providing a solid foundation in compound and aseptic operations. Roberto's education includes attendance at Cypress College.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.